Combined Cis-platinum and Alpha Interferon Therapy of Advanced Hepatocellular Carcinoma

To evaluate the clinical efficacy of α-inferferon(IFN-α) plus cis-platinum in hepatocellular carcinoma (HCC), 56 inoperable patients with HCC were divided into IFN-α plus cis-platinum treated group (n=30) and no antitumor therapy group (n=26). The survival of IFN-α plus cis-platinum treated patients was significantly better than that of patients who received no antitumor therapy (p=0.001). Median survival time was 33 weeks and 14.0 weeks, respectively. The cumulative estimated survival rates of our IFN-α plus cis-platinum treated group (93.5% at 3mo. 75.0% at 6mo) were for longer than that of the no antitumor therapy group (84.6% at 3mo, 57.7% at 6mo). Objective tumor regression, greater than 50%. was observed in 13.3% (4 of 30) of patients receiving IFN-α plus cis-platinum. By the univariate analysis, the absence of portal vein thrombus (p<0.05). alkaline phosphatase lesser than 280 U/L (p=0.001), total bilirubin less than 2.0 mg% (p<0.05). serum triglyceride less than 155 mg/dl (p<0.05) were shown to be the factors most significantly favoring a better survival. By the multivariate analysis, using Cox proportional hazards model, IFN-α plus cis-platinum treated group (p=0.0001). alkaline phosphatase less than 280 mg/dl (p=0.005, the absence of portal vein thrombus (p=0.020) were independent favorable prognostic factors. We conclude that IFN-α plus cis-platinum is useful in patients with inoperable HCC and the above favorable prognostic factors may also be useful in the design and analysis of future clinical trials of systemic chemotherapy for HCC